Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006929 · ClinicalTrials.gov registry record · Phase 2
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00006929: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006929 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006929, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG carboplatin
- DRUG paclitaxel
- OTHER pharmacological study
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006929
The ClinicalTrials.gov registry entry for NCT00006929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00006929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006929 about?
NCT00006929 is a clinical study titled "Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more tha...
What is the current status of trial NCT00006929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2000-09.
What interventions are being tested in trial NCT00006929?
The interventions under investigation include: laboratory biomarker analysis (OTHER), carboplatin (DRUG), paclitaxel (DRUG), pharmacological study (OTHER), suramin (DRUG).
Who is sponsoring clinical trial NCT00006929?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.